ATTD 2021: Adocia Oral Presentation on M1Pram Wednesday, June 2nd

Next June 2-5, 2021, at the occasion of the Virtual Event ATTD 2021, Adocia is pleased to present the following study: ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS INSULIN ASPART IN TYPE 1 DIABETES (T1D) 

The International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) has become the premier international forum to present and discuss innovative technologies and comprehensive overview of the latest research developments in this field. The purpose of the meeting is to discuss and disseminate information on the latest technologies and treatments for diabetes.

Read more information about program and registration on this link: https://attd.kenes.com/

• Session: 0060 – Oral Presentation 02
  Speaker: Dr Gregory Meiffren Date & Time: Wednesday 2 June 7.45pm – 7.55pm CEST
  Room: Hall B
  Oral Presentation: #498 – ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS INSULIN ASPART IN TYPE 1 DIABETES (T1D)
  Duration: 10 min
• Scientific Program: https://cslide.ctimeetingtech.com/attd2021/attendee/confcal/session/calendar/2021-06-02